Alnylam Pharmaceuticals
ALNY
#1138
Rank
NZ$36.11 B
Marketcap
NZ$269.67
Share price
-1.06%
Change (1 day)
-67.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): NZ$2.13 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$5.01 Billion. In 2025 the company made an earning of NZ$1.30 Billion, an increase over its 2024 earnings that were of -NZ$0.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$2.13 B64.12%
2025 NZ$1.30 B-403.41%
2024 -NZ$0.43 Billion-24.59%
2023 -NZ$0.57 Billion-67.84%
2022 -NZ$1.78 Billion36.93%
2021 -NZ$1.3 Billion-8.04%
2020 -NZ$1.41 Billion-15.66%
2019 -NZ$1.67 Billion12.23%
2018 -NZ$1.49 Billion62.91%
2017 -NZ$0.92 Billion17.78%
2016 -NZ$0.78 Billion43.44%
2015 -NZ$0.55 Billion60.69%
2014 -NZ$0.34 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$0.11 Billion27.48%
2010 -NZ$78.45 Million-10.92%
2009 -NZ$88.07 Million95.77%
2008 -NZ$44.99 Million
2006 -NZ$72.07 Million-9.13%
2005 -NZ$79.31 Million34.74%
2004 -NZ$58.86 Million36.79%
2003 -NZ$43.03 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$23.06 B 935.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$14.20 B 537.61%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$10.37 B 365.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$0.24 Billion-110.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$86.53 Million-103.88%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.3 Billion-113.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.23 B 0.21%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-NZ$0.3 Billion-113.06%๐Ÿ‡บ๐Ÿ‡ธ USA